XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.21.2

SEGMENT INFORMATION | 9 Months Ended
--- | ---
Jul. 31, 2021
Segment Reporting [Abstract] |
SEGMENT INFORMATION |
11. | SEGMENT INFORMATION
We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer Diagnostics and (v) Patent Licensing activities. The following represents selected financial information for our segments for the three and nine months ended July 31, 2021 and 2020 and as of July 31, 2021 and October 31, 2020: SCHEDULE OF SEGMENT INFORMATION
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
|  | For the Three Months Ended July 31, |  |  | For the Nine Months Ended July 31, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Net Income/(Loss): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CAR-T Therapeutics |  | $ | (1,618,860 | ) |  | $ | (417,502 | ) |  | $ | (4,025,354 | ) |  | $ | (1,542,865 | )
Cancer Vaccines |  |  | (1,464,323 | ) |  |  | (178,738 | ) |  |  | (3,033,026 | ) |  |  | (544,605 | )
Anti-Viral Therapeutics |  |  | (1,262,260 | ) |  |  | (281,098 | ) |  |  | (2,052,821 | ) |  |  | (590,602 | )
Cancer Diagnostics |  |  | (38,198 | ) |  |  | (1,693,304 | ) |  |  | (60,569 | ) |  |  | (5,162,977 | )
Patent Licensing |  |  | (3,969 | ) |  |  | (6,145 | ) |  |  | 114,894 |  |  |  | (10,303 | )
Total |  | $ | (4,387,610 | ) |  | $ | (2,576,787 | ) |  | $ | (9,056,876 | ) |  | $ | (7,851,352 | )
Net Income/(Loss) |  | $ | (4,387,610 | ) |  | $ | (2,576,787 | ) |  | $ | (9,056,876 | ) |  | $ | (7,851,352 | )
Total operating costs and expenses |  | $ | 4,388,236 |  |  | $ | 2,435,969 |  |  | $ | 9,571,149 |  |  | $ | 7,735,975 |
Less non-cash share-based compensation |  |  | (3,187,326 | ) |  |  | (1,041,799 | ) |  |  | (5,224,697 | ) |  |  | (3,173,219 | )
Operating costs and expenses excluding non-cash share-based compensation |  | $ | 1,200,910 |  |  | $ | 1,394,170 |  |  | $ | 4,346,452 |  |  | $ | 4,562,756 |
Operating costs and expenses excluding non-cash share-based compensation: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
CAR-T Therapeutics |  | $ | 411,313 |  |  | $ | 189,589 |  |  | $ | 1,903,707 |  |  | $ | 759,752 |
Cancer Vaccines |  |  | 348,535 |  |  |  | 72,968 |  |  |  | 1,185,060 |  |  |  | 238,297 |
Anti-Viral Therapeutics |  |  | 418,285 |  |  |  | 155,224 |  |  |  | 826,716 |  |  |  | 376,242 |
Cancer Diagnostics |  |  | 20,645 |  |  |  | 971,698 |  |  |  | 37,368 |  |  |  | 3,180,511 |
Patent Licensing |  |  | 2,132 |  |  |  | 4,691 |  |  |  | 393,601 |  |  |  | 7,954 |
Total |  | $ | 1,200,910 |  |  | $ | 1,394,170 |  |  |  | 4,346,452 |  |  | $ | 4,562,756 |
Operating costs and expenses excluding non-cash share-based compensation |  | $ | 1,200,910 |  |  | $ | 1,394,170 |  |  |  | 4,346,452 |  |  | $ | 4,562,756 |
|  | July 31, 2021 |  |  | October 31, 2020 |
Total assets: |  |  |  |  |  |  |  |
CAR-T Therapeutics |  | $ | 12,709,167 |  |  | $ | 2,988,124 |
Cancer Vaccines |  |  | 10,706,026 |  |  |  | 946,923 |
Anti-Viral Therapeutics |  |  | 12,849,445 |  |  |  | 2,464,361 |
Cancer Diagnostics |  |  | 682,943 |  |  |  | 2,869,529 |
Patent Licensing |  |  | 114,810 |  |  |  | 184,027 |
Total |  | $ | 37,062,391 |  |  | $ | 9,452,964 |
Total assets |  | $ | 37,062,391 |  |  | $ | 9,452,964 |
Operating costs and expenses excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration